{{Rsnum
|rsid=6604026
|Gene=RPL5
|Chromosome=1
|position=92838046
|Orientation=plus
|GMAF=0.2167
|Gene_s=FAM69A,RPL5
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 7.1 | 42.5 | 50.4
| HCB | 0.0 | 0.7 | 99.3
| JPT | 0.0 | 0.9 | 99.1
| YRI | 8.2 | 42.9 | 49.0
| ASW | 7.0 | 36.8 | 56.1
| CHB | 0.0 | 0.7 | 99.3
| CHD | 0.0 | 0.9 | 99.1
| GIH | 3.0 | 25.7 | 71.3
| LWK | 11.8 | 46.4 | 41.8
| MEX | 3.4 | 24.1 | 72.4
| MKK | 9.0 | 44.2 | 46.8
| TSI | 5.9 | 39.2 | 54.9
| HapMapRevision=28
}}[[rs6604026]] has been reported in a large study to be associated with [[multiple sclerosis]].

The risk allele (oriented to the dbSNP entry) is (C); the odds ratio associated with this allele is 1.15 (CI 1.08-1.22). {{PMID|17660530}}

{{GWAS Summary
|SNP=rs6604026
|PubMedID=17660530
|Condition=Multiple sclerosis
|Gene=RPL5
|Risk Allele=C
|pValue=8.00E-006
|OR=1.15
|95CI=1.08-1.22
}}

{{PMID Auto GWAS
|PMID=19525955
|Trait=Multiple sclerosis
|Title=Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20
|RiskAllele=G
|Pval=0.000003
|OR=1.17
|ORtxt=[NR]
}}
{{PMID Auto
|PMID=18650830
|Title=Replication of KIAA0350, IL2RA, RPL5 and CD58 as multiple sclerosis susceptibility genes in Australians
}}

{{PharmGKB
|RSID=rs6604026
|Name_s=
|Gene_s=RPL5, SNORD21, FAM69A, SNORA66
|Feature=
|Evidence=PubMed ID:17660530; Web Resource:http://www.genome.gov/gwastudies/
|Annotation=GWAS Results: Risk alleles for multiple sclerosis identified by a genomewide study (Initial Sample Size: 931 trios, 2,431 controls; Replication Sample Size: 609 trios, 2,322 cases, 2,987 controls; Risk Allele: rs6604026-C).
|Drugs=
|Drug Classes=
|Diseases=Multiple Sclerosis
|Curation Level=Non-Curated
|PharmGKB Accession ID=PA162356685
}}

{{PharmGKB
|RSID=rs6604026
|Name_s=
|Gene_s=RPL5, SNORD21, FAM69A, SNORA66
|Feature=
|Evidence=PubMed ID:17660530
|Annotation=In a replicated GWAS of U.K. and U.S. case/parent trios, this variant was shown to be associated with multiple sclerosis risk.
|Drugs=
|Drug Classes=
|Diseases=Multiple Sclerosis
|Curation Level=Curated
|PharmGKB Accession ID=PA162356162
}}

{{PMID Auto
|PMID=20368992
|Title=Multiple sclerosis susceptibility-associated SNPs do not influence disease severity measures in a cohort of Australian MS patients.
|OA=1
}}

{{PMID Auto
|PMID=20405052
|Title=The effect of single nucleotide polymorphisms from genome wide association studies in multiple sclerosis on gene expression.
|OA=1
}}

{{GET Evidence
|impact=pathogenic
|qualified_impact=Insufficiently evaluated pathogenic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs6604026
|overall_frequency_n=31
|overall_frequency_d=128
|overall_frequency=0.242188
|n_genomes=25
|n_genomes_annotated=0
|n_haplomes=28
|n_articles=1
|n_articles_annotated=0
|in_gwas=Y
|in_pharmgkb=Y
|autoscore=2
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}